Advertisement

Topics

Bayer and Loxo Oncology to Co-Develop Cancer Drugs in up to $1.55 Billion Deal

09:59 EST 15 Nov 2017 | Speciality Pharma Journal

WHIPPANY, N.J., Nov. 14, 2017 /PRNewswire/ — Bayer announced today that the company has entered into an exclusive global collaboration with Loxo Oncology, Inc., a biopharmaceutical company based in Stamford, Connecticut (NASDAQ: LOXO) for the development and commercialization of larotrectinib (LOXO-101) and LOXO-195. Both compounds are being investigated in global studies for the treatment of …

Original Article: Bayer and Loxo Oncology to Co-Develop Cancer Drugs in up to $1.55 Billion Deal

NEXT ARTICLE

More From BioPortfolio on "Bayer and Loxo Oncology to Co-Develop Cancer Drugs in up to $1.55 Billion Deal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...